Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIRT 2584 XX
- Development stage
- Phase 2
- Lead developer
- Boehringer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BIRT 2584 XX is a small molecule integrin inhibitor developed by Boehringer Ingelheim. It acts as an antagonist of the integrin alpha-L/beta-2 complex (also known as LFA-1, composed of ITGAL and ITGB2 subunits), which plays a key role in leukocyte adhesion and migration during inflammatory responses. By blocking this interaction, BIRT 2584 XX inhibits the activation and recruitment of local inflammatory cells, potentially reducing inflammation in diseases such as psoriasis. The drug has been evaluated primarily for its safety, pharmacokinetics, and efficacy in clinical trials involving patients with psoriasis[1][2][5][6].
- Other names
- BIRT2584BIRT-2584BIRT 2584
02
Targets
LFA-1 (Integrin αLβ2)
Beyond the preview
Go deeper on BIRT 2584 XX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIRT 2584 XX.